FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2419652250> ?p ?o ?g. }

• W2419652250 endingPage "104" @default.
• W2419652250 startingPage "2097" @default.
• W2419652250 abstract "Chimeric T84.66 (cT84.66) is a high-affinity (1.16x10(11) M(-1)) IgG1 monoclonal antibody against carcinoembryonic antigen (CEA). The purpose of this pilot trial was to evaluate the tumor-targeting properties, biodistribution, pharmacokinetics and immunogenicity of 111In-labeled cT84.66 as a function of administered antibody protein dose.Patients with CEA-producing colorectal cancers with localized disease or limited metastatic disease who were scheduled to undergo definitive surgical resection were each administered a single intravenous dose of 5 mg of isothiocyanatobenzyl diethylenetriaminepentaacetic acid-cT84.66, labeled with 5 mCi of 111In. Before receiving the radiolabeled antibody, patients received unlabeled diethylenetriaminepentaacetic acid-cT84.66. The amount of unlabeled antibody was 0, 20 or 100 mg, with five patients at each level. Serial blood samples, 24-hr urine collections and nuclear images were collected until 7 days postinfusion. Human antichimeric antibody response was assessed up to 6 mo postinfusion.Imaging of at least one known tumor site was performed in all 15 patients. Fifty-two lesions were analyzed, with an imaging sensitivity rate of 50.0% and a positive predictive value of 76.9%. The antibody detected tumors that were not detected by conventional means in three patients, resulting in a modification of surgical management. Interpatient variations in serum clearance rates were observed and were secondary to differences in clearance and metabolic rates of antibody and antibody:antigen complexes by the liver. Antibody uptake in primary tumors, metastatic sites and regional metastatic lymph nodes ranged from 0.4% to 134% injected dose/kg, resulting in estimated 90Y-cT84.66 radiation doses ranging from 0.3 to 193 cGy/mCi. Thirteen patients were evaluated 1-6 mo after infusion for human antichimeric antibody, and none developed a response. No major differences in tumor imaging, tumor uptake, pharmacokinetics or organ biodistribution were observed with increasing protein doses, although a trend toward increasing blood uptake and decreasing liver uptake was observed with increasing protein dose.Chimeric T84.66 demonstrated tumor targeting comparable to other radiolabeled intact anti-CEA monoclonal antibodies. Its immunogenicity after single administration was lower than murine monoclonal antibodies. These properties make 111In-cT84.66, or a lower molecular weight derivative, attractive for further evaluation as an imaging agent. Yttrium-90 dosimetry estimates predict potentially cytotoxic radiation doses to select tumor sites, which makes 90Y-cT84.66 also appropriate for further evaluation in Phase I radioimmunotherapy trials. Although clinically important changes in biodistribution, pharmacokinetics and tumor targeting with increasing protein doses of 111In-cT84.66 were not demonstrated, the results do suggest that antibody clearance from the blood is driven by hepatic uptake and metabolism, with more rapid blood clearance seen in patients with liver metastases. These patients with rapid clearance and potentially unfavorable biodistribution for imaging and therapy may, therefore, be a more appropriate subset in which to evaluate the role of administering higher protein doses. This underscores the need to further identify, characterize and understand those factors that influence the biodistribution and clearance of radiolabeled anti-CEA antibodies, to allow for better selection of patients for therapy and rational planning of radioimmunotherapy." @default.
• W2419652250 created "2016-06-24" @default.
• W2419652250 creator A5014867897 @default.
• W2419652250 creator A5016834515 @default.
• W2419652250 creator A5017822750 @default.
• W2419652250 creator A5026521311 @default.
• W2419652250 creator A5038098316 @default.
• W2419652250 creator A5065938090 @default.
• W2419652250 creator A5071244558 @default.
• W2419652250 creator A5072320451 @default.
• W2419652250 creator A5079802724 @default.
• W2419652250 creator A5080033344 @default.
• W2419652250 creator A5088599670 @default.
• W2419652250 creator A5088864581 @default.
• W2419652250 date "1998-12-01" @default.
• W2419652250 modified "2023-10-14" @default.
• W2419652250 title "Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients." @default.
• W2419652250 cites W1487905364 @default.
• W2419652250 cites W1495241273 @default.
• W2419652250 cites W1504263203 @default.
• W2419652250 cites W1515420677 @default.
• W2419652250 cites W1551923230 @default.
• W2419652250 cites W1582421378 @default.
• W2419652250 cites W1588459810 @default.
• W2419652250 cites W1866826474 @default.
• W2419652250 cites W1893112022 @default.
• W2419652250 cites W1961305805 @default.
• W2419652250 cites W1967889416 @default.
• W2419652250 cites W1976098267 @default.
• W2419652250 cites W1984025792 @default.
• W2419652250 cites W1984883977 @default.
• W2419652250 cites W2031822911 @default.
• W2419652250 cites W2040505385 @default.
• W2419652250 cites W2123725932 @default.
• W2419652250 cites W2145242672 @default.
• W2419652250 cites W2287079750 @default.
• W2419652250 cites W2293668856 @default.
• W2419652250 cites W2320751441 @default.
• W2419652250 cites W2416474163 @default.
• W2419652250 cites W2897075576 @default.
• W2419652250 cites W2116049862 @default.
• W2419652250 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9867150" @default.
• W2419652250 hasPublicationYear "1998" @default.
• W2419652250 type Work @default.
• W2419652250 sameAs 2419652250 @default.
• W2419652250 citedByCount "11" @default.
• W2419652250 countsByYear W24196522502018 @default.
• W2419652250 countsByYear W24196522502019 @default.
• W2419652250 countsByYear W24196522502022 @default.
• W2419652250 crossrefType "journal-article" @default.
• W2419652250 hasAuthorship W2419652250A5014867897 @default.
• W2419652250 hasAuthorship W2419652250A5016834515 @default.
• W2419652250 hasAuthorship W2419652250A5017822750 @default.
• W2419652250 hasAuthorship W2419652250A5026521311 @default.
• W2419652250 hasAuthorship W2419652250A5038098316 @default.
• W2419652250 hasAuthorship W2419652250A5065938090 @default.
• W2419652250 hasAuthorship W2419652250A5071244558 @default.
• W2419652250 hasAuthorship W2419652250A5072320451 @default.
• W2419652250 hasAuthorship W2419652250A5079802724 @default.
• W2419652250 hasAuthorship W2419652250A5080033344 @default.
• W2419652250 hasAuthorship W2419652250A5088599670 @default.
• W2419652250 hasAuthorship W2419652250A5088864581 @default.
• W2419652250 hasConcept C112705442 @default.
• W2419652250 hasConcept C121608353 @default.
• W2419652250 hasConcept C126322002 @default.
• W2419652250 hasConcept C142724271 @default.
• W2419652250 hasConcept C147483822 @default.
• W2419652250 hasConcept C159654299 @default.
• W2419652250 hasConcept C179223381 @default.
• W2419652250 hasConcept C185592680 @default.
• W2419652250 hasConcept C202751555 @default.
• W2419652250 hasConcept C203014093 @default.
• W2419652250 hasConcept C2776146153 @default.
• W2419652250 hasConcept C2777387746 @default.
• W2419652250 hasConcept C2777807558 @default.
• W2419652250 hasConcept C2779720271 @default.
• W2419652250 hasConcept C526805850 @default.
• W2419652250 hasConcept C542903549 @default.
• W2419652250 hasConcept C55493867 @default.
• W2419652250 hasConcept C71924100 @default.
• W2419652250 hasConcept C90924648 @default.
• W2419652250 hasConceptScore W2419652250C112705442 @default.
• W2419652250 hasConceptScore W2419652250C121608353 @default.
• W2419652250 hasConceptScore W2419652250C126322002 @default.
• W2419652250 hasConceptScore W2419652250C142724271 @default.
• W2419652250 hasConceptScore W2419652250C147483822 @default.
• W2419652250 hasConceptScore W2419652250C159654299 @default.
• W2419652250 hasConceptScore W2419652250C179223381 @default.
• W2419652250 hasConceptScore W2419652250C185592680 @default.
• W2419652250 hasConceptScore W2419652250C202751555 @default.
• W2419652250 hasConceptScore W2419652250C203014093 @default.
• W2419652250 hasConceptScore W2419652250C2776146153 @default.
• W2419652250 hasConceptScore W2419652250C2777387746 @default.
• W2419652250 hasConceptScore W2419652250C2777807558 @default.
• W2419652250 hasConceptScore W2419652250C2779720271 @default.
• W2419652250 hasConceptScore W2419652250C526805850 @default.
• W2419652250 hasConceptScore W2419652250C542903549 @default.
• W2419652250 hasConceptScore W2419652250C55493867 @default.

• next